Latest news with #NovantaInc
Business Wire
15-05-2025
- Business
- Business Wire
Novanta to Present at Baird 2025 Global Consumer, Technology & Services Conference on Wednesday, June 4, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Baird 2025 Global Consumer, Technology & Services Conference on Wednesday, June 4, 2025, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers' success. Novanta's common shares are quoted on Nasdaq under the ticker symbol 'NOVT.' More information about Novanta is available on the Company's website at For additional information, please contact Novanta Inc. Investor Relations at (781) 266-5137 or InvestorRelations@
Business Wire
13-05-2025
- Business
- Business Wire
Novanta to Present at the William Blair 45 th Annual Growth Stock Conference on Tuesday, June 3, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer is scheduled to present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3, 2025, in Chicago, IL. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers' success. Novanta's common shares are quoted on Nasdaq under the ticker symbol 'NOVT.' More information about Novanta is available on the Company's website at For additional information, please contact Novanta Inc. Investor Relations at (781) 266-5137 or InvestorRelations@
San Francisco Chronicle
06-05-2025
- Business
- San Francisco Chronicle
Novanta: Q1 Earnings Snapshot
BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Novanta Inc. (NOVT) on Tuesday reported net income of $21.2 million in its first quarter. The Bedford, Massachusetts-based company said it had profit of 59 cents per share. Earnings, adjusted for one-time gains and costs, came to 74 cents per share. The photonic and motion control components maker posted revenue of $233.4 million in the period. For the current quarter ending in June, Novanta expects its per-share earnings to range from 68 cents to 78 cents.
Yahoo
28-02-2025
- Business
- Yahoo
Analyst Estimates: Here's What Brokers Think Of Novanta Inc. (NASDAQ:NOVT) After Its Yearly Report
Last week saw the newest yearly earnings release from Novanta Inc. (NASDAQ:NOVT), an important milestone in the company's journey to build a stronger business. Novanta reported in line with analyst predictions, delivering revenues of US$949m and statutory earnings per share of US$1.77, suggesting the business is executing well and in line with its plan. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year. Check out our latest analysis for Novanta After the latest results, the four analysts covering Novanta are now predicting revenues of US$1.02b in 2025. If met, this would reflect an okay 7.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to bounce 34% to US$2.40. In the lead-up to this report, the analysts had been modelling revenues of US$1.04b and earnings per share (EPS) of US$2.66 in 2025. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts. The consensus price target held steady at US$164, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Novanta at US$185 per share, while the most bearish prices it at US$138. This is a very narrow spread of estimates, implying either that Novanta is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions. Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Novanta's revenue growth is expected to slow, with the forecast 7.6% annualised growth rate until the end of 2025 being well below the historical 11% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 7.3% annually. So it's pretty clear that, while Novanta's revenue growth is expected to slow, it's expected to grow roughly in line with the industry. The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Novanta. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Novanta going out to 2026, and you can see them free on our platform here. Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Novanta that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
20-02-2025
- Business
- Yahoo
Investing in Novanta (NASDAQ:NOVT) five years ago would have delivered you a 58% gain
Novanta Inc. (NASDAQ:NOVT) shareholders might be concerned after seeing the share price drop 12% in the last quarter. But at least the stock is up over the last five years. In that time, it is up 58%, which isn't bad, but is below the market return of 109%. Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business. View our latest analysis for Novanta To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. Over half a decade, Novanta managed to grow its earnings per share at 6.3% a year. This EPS growth is lower than the 10% average annual increase in the share price. So it's fair to assume the market has a higher opinion of the business than it did five years ago. That's not necessarily surprising considering the five-year track record of earnings growth. This optimism is visible in its fairly high P/E ratio of 86.74. You can see below how EPS has changed over time (discover the exact values by clicking on the image). Dive deeper into Novanta's key metrics by checking this interactive graph of Novanta's earnings, revenue and cash flow. Investors in Novanta had a tough year, with a total loss of 7.8%, against a market gain of about 26%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 10% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Novanta better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Novanta , and understanding them should be part of your investment process. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
